Hims & Hers Health (NYSE:HIMS) Issues Quarterly Earnings Results

Hims & Hers Health (NYSE:HIMS) posted its quarterly earnings data on Monday. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03, Briefing.com reports. The company had revenue of $278.20 million during the quarter, compared to analysts’ expectations of $270.37 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The firm’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same period last year, the firm earned ($0.05) EPS. Hims & Hers Health updated its FY 2024 guidance to EPS and its Q2 2024 guidance to EPS.

Hims & Hers Health Price Performance

HIMS traded up $0.63 on Thursday, reaching $12.78. 3,827,876 shares of the company traded hands, compared to its average volume of 5,143,353. The stock’s 50 day moving average price is $13.99 and its 200-day moving average price is $10.41. The company has a market cap of $2.74 billion, a price-to-earnings ratio of -110.55 and a beta of 0.97. Hims & Hers Health has a 52-week low of $5.65 and a 52-week high of $17.16.

Analysts Set New Price Targets

HIMS has been the topic of a number of analyst reports. Guggenheim lifted their price objective on shares of Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Canaccord Genuity Group started coverage on shares of Hims & Hers Health in a research report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price objective for the company. Leerink Partnrs restated a “market perform” rating on shares of Hims & Hers Health in a research report on Monday, February 26th. TheStreet upgraded shares of Hims & Hers Health from a “d” rating to a “c” rating in a research note on Monday, March 4th. Finally, Piper Sandler upped their target price on shares of Hims & Hers Health from $11.00 to $13.00 and gave the stock a “neutral” rating in a research report on Tuesday. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health has an average rating of “Moderate Buy” and an average target price of $15.07.

Insider Activity

In other Hims & Hers Health news, COO Melissa Baird sold 11,750 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $12.08, for a total value of $141,940.00. Following the completion of the sale, the chief operating officer now directly owns 538,932 shares in the company, valued at $6,510,298.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, COO Melissa Baird sold 11,750 shares of the firm’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $12.08, for a total value of $141,940.00. Following the transaction, the chief operating officer now directly owns 538,932 shares in the company, valued at approximately $6,510,298.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Soleil Boughton sold 22,839 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $10.03, for a total value of $229,075.17. Following the sale, the insider now owns 154,345 shares of the company’s stock, valued at approximately $1,548,080.35. The disclosure for this sale can be found here. Insiders have sold a total of 736,191 shares of company stock worth $9,733,700 in the last ninety days. Corporate insiders own 31.63% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.